{"gene":"CYP3A5","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2001,"finding":"A SNP within intron 3 (g.6986G>A, CYP3A5*3) is the primary genetic cause of the CYP3A5 protein polymorphism; the *3 allele leads to improper mRNA splicing and consequent loss of CYP3A5 protein expression, while the *1 allele permits normal splicing and protein expression.","method":"High-density SNP mapping of CYP3A5 variants in 183 Caucasian liver samples correlated with CYP3A5 protein expression; ethnic allele frequency analysis","journal":"Pharmacogenetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated independently across multiple labs and ethnic groups, with direct genotype-phenotype correlation in large tissue panels","pmids":["11740341"],"is_preprint":false},{"year":2002,"finding":"CYP3A5 protein contributes substantially (~31%) to the variability in hepatic midazolam 1'-hydroxylation activity; in livers carrying at least one CYP3A5*1 allele, CYP3A5 represented >50% of total CYP3A content, and improperly spliced mRNA (SV1-CYP3A5) was found only in tissues carrying a CYP3A5*3 allele.","method":"Quantitative protein and mRNA analysis of a panel of human liver and jejunal samples with genotype stratification; midazolam hydroxylation activity assays in liver microsomes","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (protein quantification, mRNA analysis, functional enzyme assay) in well-characterized tissue bank with genotype stratification","pmids":["12065767"],"is_preprint":false},{"year":2005,"finding":"CYP3A5 mRNA splice variants containing exon 3B (arising from the CYP3A5*3 allele) are degraded by nonsense-mediated mRNA decay (NMD) due to premature termination codons in exon 3B; cycloheximide (ribosome inhibitor) and UPF1 siRNA both reduced decay of these splice variants, confirming NMD involvement. Barbiturate or steroid induction did not switch on CYP3A5 phenotypic expression in *3/*3 carriers.","method":"CYP3A5 minigene transfection in MCF7 cells; endogenous gene in HepG2 cells; cycloheximide treatment; UPF1 siRNA knockdown; PTC mutagenesis of exon 3B","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal mechanistic approaches (minigene, siRNA, mutagenesis, pharmacological inhibition) in one study, confirming NMD as the degradation mechanism","pmids":["15955870"],"is_preprint":false},{"year":2006,"finding":"CYP3A5 metabolizes tacrolimus with a catalytic efficiency (Vmax/Km) approximately 64% higher than CYP3A4 for 13-O-demethyltacrolimus formation; CYP3A5 contributes 1.5–40% (median 18.8%) of total hepatic 13-O-demethylation of tacrolimus, and mean in vivo hepatic clearance is approximately 2.4-fold higher in CYP3A5 expressors versus non-expressors.","method":"In vitro kinetics with cDNA-expressed CYP3A4, CYP3A5, and CYP3A7; human liver microsomes stratified by CYP3A5 genotype; LC-MS/MS metabolite quantification; parallel-tube liver model scaling","journal":"Clinical chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro kinetic characterization with recombinant enzymes and genotyped microsomes, replicated by independent group (PMID 16501005)","pmids":["15951320","16501005"],"is_preprint":false},{"year":2006,"finding":"Recombinant CYP3A5 generates tacrolimus metabolites 13-O-desmethyl tacrolimus (major), 15-O-desmethyl tacrolimus, 31-O-desmethyl tacrolimus, and 12-hydroxy tacrolimus with an intrinsic clearance twice that of CYP3A4; formation of 13-DMT, 31-DMT, and 12-HT was ≥1.7-fold higher in CYP3A5*1/*3 microsomes than in *3/*3 microsomes. CYP3A5 also contributes substantially to renal tacrolimus metabolism (13-DMT formation 13.5-fold higher in *1/*3 kidney microsomes).","method":"In vitro enzyme kinetics with heterologously expressed CYP3A4 and CYP3A5; genotyped human liver and kidney microsomes; metabolite identification and quantification","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted enzyme kinetics with recombinant proteins plus genotyped human tissue microsomes, two independent datasets","pmids":["16501005"],"is_preprint":false},{"year":2007,"finding":"CYP3A5 preferentially metabolizes vincristine to a secondary amine metabolite (M1) with 9- to 14-fold higher intrinsic clearance than CYP3A4 using cDNA-expressed enzymes; in CYP3A5 high-expressers, CYP3A5 accounts for 54–95% of total M1 formation activity, and the rate of M1 formation correlates tightly with CYP3A5 protein content (r²=0.95). Estimated hepatic clearance is ~5-fold higher in CYP3A5 high-expressers.","method":"cDNA-expressed enzyme kinetics; genotyped human liver microsome bank; Western blot protein quantification; selective chemical inhibition; linear regression analysis","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — recombinant enzyme kinetics combined with genotyped microsomal bank and selective chemical inhibition, single lab","pmids":["17272675"],"is_preprint":false},{"year":2005,"finding":"Verapamil and its metabolite N-desalkylverapamil (D617) have little inhibitory effect on CYP3A5 and do not form a metabolic-intermediate complex (MIC) with CYP3A5, in contrast to their potent mechanism-based inhibition of CYP3A4. Norverapamil causes only modest time-dependent inhibition of CYP3A5 (30% at 50 µM) versus 80% for CYP3A4, with inactivation efficiency ~45-fold lower for CYP3A5. Human liver microsomes expressing CYP3A5 are correspondingly less inhibited by verapamil.","method":"cDNA-expressed CYP3A4 and CYP3A5 enzyme assays; dual-beam spectrophotometry for MIC detection; time-dependent inhibition kinetics (kinact, KI determination); genotyped human liver microsomes","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with recombinant enzymes, MIC spectrophotometry, kinetic parameter determination, and human microsome validation in a single focused study","pmids":["15689501"],"is_preprint":false},{"year":2008,"finding":"CYP3A5 metabolizes quetiapine with an intrinsic clearance <35% of CYP3A4; CYP3A5 produces a different metabolite pattern (higher proportion of O-desalkylquetiapine relative to CYP3A4); cytochrome b5 co-expression increases CYP3A4 CL_int ~3-fold but has no effect on CYP3A5 CL_int, revealing a distinct interaction of CYP3A5 with cytochrome b5.","method":"Substrate depletion kinetics in insect cell microsomes expressing CYP3A4 or CYP3A5 ± cytochrome b5; metabolite profiling","journal":"Drug metabolism and disposition","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous in vitro kinetics with recombinant enzymes and orthogonal metabolite profiling, but single lab, single study","pmids":["19022943"],"is_preprint":false},{"year":2013,"finding":"CYP3A5 contributes to the formation of secondary cyclosporine A metabolites AM19 and AM1c9 (from AM1 and AM1c precursors); CYP3A5 expressors have ~47–51% higher AUC for AM19 and AM1c9 versus non-expressors in vivo, and ~20% lower apparent urinary CsA clearance, indicating CYP3A5-dependent intrarenal CsA metabolism.","method":"Oral CsA administration to 24 healthy volunteers stratified by CYP3A5 genotype; whole blood/urine metabolite measurement by LC-MS; in vitro incubations of CsA metabolites with recombinant CYP3A4 and CYP3A5","journal":"Transplantation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — combined in vitro recombinant enzyme studies and controlled human pharmacokinetic study with genotype stratification","pmids":["23354298"],"is_preprint":false},{"year":2016,"finding":"CYP3A5 mediates intrinsic and acquired drug resistance in pancreatic ductal adenocarcinoma by metabolically inactivating tyrosine kinase inhibitors and paclitaxel; CYP3A5 basal expression is controlled by HNF4A, while drug-induced upregulation is mediated by nuclear receptor NR1I2 (PXR); shRNA or pharmacological CYP3A5 inhibition re-sensitizes resistant tumor cells to these drugs.","method":"Patient-derived tumor cell models; shRNA knockdown; pharmacological inhibition; mechanistic dissection of HNF4A and NR1I2 regulation; drug sensitivity assays","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (shRNA, pharmacological inhibition, transcription factor dissection) in patient-derived models, published in high-impact peer-reviewed journal","pmids":["26855150"],"is_preprint":false},{"year":2001,"finding":"Transcription of the CYP3A5 gene is cooperatively regulated by NF-Y (binding CCAAT box at -78/-68) and Sp1/Sp3 (binding the basic transcription element BTE at -67/-46) in HepG2 cells; mutation of either element alone decreases transcriptional activity to 10–21% of wild-type, while mutation of both reduces it to 4%.","method":"5'-truncated promoter-luciferase chimeric gene transfection in HepG2 cells; gel shift assays (EMSA) with nuclear extracts; site-directed mutagenesis of CCAAT box and BTE","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — promoter deletion analysis, EMSA, and mutagenesis in combination in a single focused study","pmids":["11485307"],"is_preprint":false},{"year":2006,"finding":"CYP3A5 expression in human prostate is androgen-regulated: an androgen response element (ARE) in the CYP3A5 proximal promoter binds the androgen receptor (AR) as shown by EMSA, and androgen induction is abolished by mutation of this element. CYP3A5 mRNA is induced in LNCaP cells by androgen, suggesting CYP3A5 participates in an autoregulatory feedback loop controlling prostate cell androgen exposure by metabolizing testosterone.","method":"GeneChip analysis of prostate tissue after castration; RT-PCR of LNCaP cells; EMSA with ARE and AR; promoter mutation analysis; immunoblotting; immunohistochemistry; in situ hybridization","journal":"Carcinogenesis","confidence":"High","confidence_rationale":"Tier 1 / Moderate — EMSA plus promoter mutagenesis establishing direct AR binding and androgen-dependent transcriptional control, supported by in vivo tissue data","pmids":["17116727"],"is_preprint":false},{"year":2013,"finding":"CYP3A5 expression in human hepatocytes is sexually dimorphic (women > men), attributable to ~2-fold greater hormone-induced activation and nuclear accumulation of HNF-4α, PXR, and RXRα in female hepatocytes; PXR:RXRα shows higher DNA binding to its motif on the CYP3A5 promoter in female hepatocytes; HNF-4α siRNA knockdown and luciferase reporter assays confirmed this mechanism.","method":"Primary human hepatocyte cultures from male and female donors; nuclear translocation assays; EMSA/promoter binding assays; HNF-4α siRNA knockdown; CYP3A5 promoter-luciferase reporter in HepG2 cells","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal nuclear localization + promoter binding + siRNA + reporter assays, multiple orthogonal methods, single lab","pmids":["22994453"],"is_preprint":false},{"year":2015,"finding":"CYP3A5 regulates androgen receptor (AR) nuclear translocation in prostate cancer cells; CYP3A5 siRNA or the CYP3A5 inhibitor azamulin reduced growth of LNCaP, C4-2, and 22RV1 cells by 30–60%, decreased AR nuclear localization in response to DHT/R1881, and diminished PSA and TMPRSS2 expression. Conversely, the CYP3A5 inducer rifampicin enhanced AR nuclear localization.","method":"CYP3A5 siRNA knockdown; pharmacological inhibition (azamulin); CYP3A5 induction (rifampicin); cell fractionation; immunocytochemistry; growth assays; downstream AR target gene expression","journal":"The Prostate","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA plus pharmacological modulation with multiple cellular readouts (localization, growth, target genes), single lab","pmids":["25586052"],"is_preprint":false},{"year":2015,"finding":"CYP3A5 mediates the bioactivation and cytotoxicity of the bisbenzylisoquinoline alkaloid tetrandrine by generating a reactive quinone methide intermediate; a WI-38 cell line transgenically expressing Cyp3a5 showed higher ROS, higher LDH release, lower GSH, and more apoptosis (elevated caspase-3, reduced Bcl-2) than vector-transfected controls after tetrandrine treatment.","method":"Cyp3a5-transgenic WI-38 cell line; ROS measurement; LDH assay; GSH assay; caspase-3 and Bcl-2 Western blot; apoptosis flow cytometry","journal":"Archives of toxicology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isogenic cell model with multiple orthogonal cytotoxicity readouts, single lab","pmids":["26302866"],"is_preprint":false},{"year":2016,"finding":"Both CYP3A4 and CYP3A5 bioactivate lapatinib via O-dealkylation to a reactive quinoneimine that forms glutathione adducts, but CYP3A4 is ~4–5-fold more efficient (kcat/Km) than CYP3A5 for both O-dealkylation and GSH adduct formation; CYP3A4-selective inhibitors reduced GSH adduct formation by 72–78% versus >90% for pan-CYP3A inhibition, indicating the remaining 16–22% is CYP3A5-mediated.","method":"cDNA-expressed recombinant P450 panel; Km/kcat kinetics; LC-MS/MS metabolite and GSH adduct quantification; CYP3A4-selective inhibitors (SR-9186, CYP3cide) in pooled human liver microsomes","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted enzyme kinetics with recombinant proteins, selective chemical inhibitors, and mass spectrometric metabolite quantification in one study","pmids":["27450182"],"is_preprint":false},{"year":2013,"finding":"CYP3A4 and CYP3A5 both oxidize vinorelbine with equivalent Michaelis-Menten constants in recombinant systems (Km ~2.6 vs 3.6 µM; common Vmax ~1.4 pmol/min/pmol), but produce qualitatively different metabolite patterns; in human liver microsomes, intrinsic clearance correlates with CYP3A4 activity and does not significantly differ between CYP3A5 high and low expressers, indicating minimal contribution of polymorphic CYP3A5 to systemic vinorelbine clearance.","method":"cDNA-expressed CYP3A4+b5 and CYP3A5+b5 kinetics; radiolabeled vinorelbine; NMR and mass spectrometry metabolite characterization; genotyped human liver microsomes; CYP3A4 activity correlation","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous in vitro reconstitution with structural metabolite characterization plus human microsomal validation, single lab","pmids":["23780963"],"is_preprint":false},{"year":2019,"finding":"The X-ray crystal structure of substrate-free CYP3A5 (2.20 Å) reveals a larger active site and an open substrate access channel compared with substrate-free CYP3A4, arising partly from a higher trajectory of the helix F-F' connector and fewer π-CH interactions between phenylalanine residues forming the active-site roof in CYP3A5; comparison with the CYP3A5-ritonavir complex confirmed conserved structural features and differential plasticity that favors alternative ritonavir conformations compared with CYP3A4.","method":"X-ray crystallography of substrate-free CYP3A5 (2.20 Å); structural comparison with CYP3A5-ritonavir complex and CYP3A4 structures","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — high-resolution crystal structure with comparative structural analysis and functional interpretation, single lab but rigorous method","pmids":["30926609"],"is_preprint":false},{"year":2019,"finding":"The relative contribution of CYP3A5 to 21-hydroxyeplerenone formation (Vmax/KM = 3.3) exceeds that of CYP3A4 (Vmax/KM = 1.9), while the 6β-hydroxyeplerenone metabolite is formed preferentially by CYP3A4, establishing eplerenone as a substrate with differential positional selectivity between the two CYP3A isoforms.","method":"In vitro microsomal incubations with recombinant CYP3A4 and CYP3A5; metabolite identification and kinetic parameter determination","journal":"Toxicology letters","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — well-executed in vitro enzyme kinetics with recombinant enzymes, but single lab, focused on one substrate","pmids":["31408697"],"is_preprint":false},{"year":1997,"finding":"CYP3A5 is the predominant CYP3A form expressed in human lung (mRNA detected in all 8 samples by RT-PCR), localized by immunohistochemistry to ciliated and mucous bronchial cells, bronchial glands, bronchiolar epithelium, alveolar type I and II epithelium, vascular and capillary endothelium, and alveolar macrophages, whereas CYP3A4 is expressed in only ~20% of individuals and in fewer cell types.","method":"Immunohistochemistry with CYP3A4- and CYP3A5-specific antipeptide antibodies; RT-PCR with gene-specific primers in human lung tissue","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal methods (IHC and RT-PCR) for localization in human tissue, single study but comprehensive cell-type characterization","pmids":["9070608"],"is_preprint":false},{"year":1996,"finding":"CYP3A5 is selectively expressed in human peripheral blood, specifically in neutrophils (PMNs) but not in other blood cells; CYP3A4 is not detected in peripheral blood by PCR or immunoblot. Despite CYP3A5 protein presence in white cell homogenates, midazolam metabolism could not be detected in granulocyte or whole WBC preparations.","method":"Immunostaining of peripheral blood smears; RT-PCR with CYP3A-specific primers on PMN and mononuclear cell cDNA; immunoblotting with anti-CYP3A and anti-CYP3A5 antibodies; midazolam metabolism assay in WBC preparations","journal":"Pharmacogenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (immunostaining, PCR, immunoblot, functional assay), but functional metabolic activity was negative","pmids":["8946469"],"is_preprint":false},{"year":2022,"finding":"A distal regulatory region (DRR) ~several kb from CYP3A4 physically contacts the CYP3A4 promoter (detected by 4C chromatin conformation capture), acts as a shared transcriptional enhancer for CYP3A4, CYP3A5, and CYP3A7 (CRISPR deletion decreases expression of all three genes); SNPs rs776744/rs776742 within the DRR increase enhancer-driven reporter expression and are associated with 1.39-fold increased CYP3A5 mRNA in human liver.","method":"4C chromatin conformation capture; enhancer reporter assays; CRISPR-mediated DRR deletion; liver cohort (n=246) genotype-expression correlation; clinical cohort validation","journal":"Clinical and translational science","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal mechanistic methods (4C, CRISPR, reporter assay, mutagenesis) validated in human liver cohort","pmids":["36045613"],"is_preprint":false},{"year":2022,"finding":"A lncRNA (AC069294.1) generated antisense to CYP3A4 negatively regulates both CYP3A4 and CYP3A5 expression; knockdown of AC069294.1 in Huh7 cells increased CYP3A4 mRNA ~3-fold, while overexpression decreased CYP3A4 mRNA by 89% and also reduced CYP3A5 expression; the CYP3A4*1G SNP (rs2242480) is associated with increased AC069294.1 expression and decreased CYP3A5 mRNA by 39%.","method":"siRNA knockdown and overexpression of AC069294.1 in Huh7 cells; mRNA quantification; liver eQTL analysis; linkage disequilibrium analysis","journal":"Pharmacogenetics and genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional knockdown and overexpression with mRNA readouts plus human liver cohort correlation, single lab","pmids":["34320606"],"is_preprint":false},{"year":2015,"finding":"CYP3A5 expression in human fetal liver (7–32 weeks postconception) is highly variable (235-fold for normally spliced mRNA); alternative splicing due to the CYP3A5*3 allele occurs in fetal liver as in adults; formation of 1'-OH midazolam varies 79-fold and the 1'-OH/4-OH MDZ ratio depends on CYP3A5*3 genotype, confirming functional CYP3A5 activity in fetal liver.","method":"Genotyping of fetal liver bank; RT-PCR quantification of normal and SV1 CYP3A5 mRNA; midazolam 1'- and 4-hydroxylation activity assays in fetal liver microsomes","journal":"Drug metabolism and disposition","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — combined genotyping, mRNA quantification, and functional enzyme assay in large fetal liver bank, single lab","pmids":["25979262"],"is_preprint":false},{"year":2011,"finding":"CYP3A5 protein expression in renal tubular cells (assessed by immunohistochemistry of renal allograft biopsies) is associated with calcineurin inhibitor nephrotoxicity (CNIT): CYP3A5 positivity at the brush border of proximal tubules was present in 47% of CNIT biopsies versus 14% of controls, while distal tubule staining was reduced in CNIT (10% vs 39%), suggesting altered localization/expression pattern is linked to nephrotoxicity.","method":"Immunohistochemistry of renal allograft biopsies (n=103); genotyping for CYP3A5 and ABCB1 SNPs; correlation of protein expression with histological CNIT diagnosis","journal":"Transplantation","confidence":"Low","confidence_rationale":"Tier 3 / Weak — retrospective IHC in biopsies with no functional mechanistic follow-up; localization finding without causal mechanistic experiment","pmids":["21544031"],"is_preprint":false},{"year":1999,"finding":"CYP3A5 protein expression is detected in human skin (and tissue-engineered skin equivalents) by gene and protein expression methods; functional testosterone metabolism (confirmed by mass spectrometry of metabolites) was demonstrated in tissue-engineered skin equivalents, establishing that CYP3A5 is enzymatically active in skin.","method":"RT-PCR and protein expression in human skin and tissue-engineered skin equivalents (TESEs); enzyme activity assay with fluorescent substrate; mass spectrometric analysis of testosterone metabolites in TESE lysates","journal":"Experimental dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional enzyme activity confirmed by mass spectrometry in a relevant tissue model, single lab","pmids":["29227563"],"is_preprint":false}],"current_model":"CYP3A5 is a cytochrome P450 enzyme whose expression is primarily controlled by a common intronic splice-site variant (CYP3A5*3/g.6986G>A) that causes improper mRNA splicing and NMD-mediated degradation of aberrant transcripts; in expressors, transcription is cooperatively driven by NF-Y, Sp1/Sp3, PXR:RXRα, and HNF-4α acting on promoter elements, with an upstream distal enhancer and a cis-acting lncRNA providing additional regulatory inputs. When expressed, CYP3A5 hydroxylates and demethylates numerous drugs (notably tacrolimus, cyclosporine metabolites, vincristine, lapatinib, eplerenone, and tetrandrine) with catalytic efficiencies and positional selectivities that differ from CYP3A4, and unlike CYP3A4 is relatively resistant to mechanism-based inhibition by verapamil; in prostate cells CYP3A5 facilitates androgen receptor nuclear translocation (and is itself androgen-regulated via a promoter ARE), and in certain tumors it acts as a cell-autonomous drug-detoxification enzyme whose induction through NR1I2/PXR confers acquired drug resistance."},"narrative":{"mechanistic_narrative":"CYP3A5 is a cytochrome P450 monooxygenase that hydroxylates and demethylates a broad range of drugs and steroids, with catalytic efficiencies and positional selectivities that distinguish it from the closely related CYP3A4 [PMID:15951320, PMID:16501005, PMID:31408697]. Its expression in the population is governed primarily by the intronic CYP3A5*3 splice-site variant (g.6986G>A), which introduces aberrant exon 3B into the transcript; the resulting premature termination codons trigger UPF1-dependent nonsense-mediated decay, abolishing functional protein in *3/*3 individuals while *1 carriers retain expression [PMID:11740341, PMID:15955870]. In expressors, CYP3A5 can constitute more than half of total hepatic CYP3A and accounts for a substantial fraction of CYP3A-mediated drug metabolism [PMID:12065767]. Functionally, CYP3A5 metabolizes tacrolimus, cyclosporine-derived metabolites, and vincristine with markedly higher intrinsic clearance than CYP3A4 [PMID:15951320, PMID:16501005, PMID:17272675, PMID:23354298], produces distinct metabolite patterns for substrates such as quetiapine, vinorelbine, and eplerenone [PMID:19022943, PMID:23780963, PMID:31408697], and is relatively resistant to the mechanism-based inhibition that verapamil exerts on CYP3A4 [PMID:15689501]. Its enlarged, open active site and distinct helix F-F' geometry provide a structural basis for these isoform-specific catalytic behaviors [PMID:30926609]. Beyond constitutive hepatic and extrahepatic expression, CYP3A5 transcription is cooperatively driven by NF-Y and Sp1/Sp3 at the proximal promoter [PMID:11485307], by HNF-4α and PXR:RXRα in a sex-dependent manner [PMID:22994453], and by a shared distal enhancer and an antisense lncRNA (AC069294.1) [PMID:36045613, PMID:34320606]. CYP3A5 also participates in cell-autonomous roles: it bioactivates compounds such as tetrandrine and lapatinib to reactive intermediates [PMID:26302866, PMID:27450182], confers PXR-driven drug resistance in pancreatic tumors by inactivating chemotherapeutics [PMID:26855150], and in prostate cells facilitates androgen receptor nuclear translocation while being itself androgen-inducible through a promoter ARE [PMID:17116727, PMID:25586052].","teleology":[{"year":2001,"claim":"Established the genetic basis of the CYP3A5 expression polymorphism, answering why only a subset of individuals express functional protein.","evidence":"High-density SNP mapping correlated with protein expression in 183 liver samples","pmids":["11740341"],"confidence":"High","gaps":["Did not establish the molecular fate of the aberrant transcript","Did not address regulation in expressors"]},{"year":2001,"claim":"Identified the core transcription factors driving CYP3A5 basal promoter activity, defining how the gene is expressed when permitted.","evidence":"Promoter-luciferase truncations, EMSA, and site-directed mutagenesis in HepG2 cells","pmids":["11485307"],"confidence":"High","gaps":["Did not address inducible or nuclear-receptor-mediated regulation","No distal regulatory elements examined"]},{"year":2002,"claim":"Quantified the contribution of CYP3A5 to hepatic CYP3A activity, showing it is a major determinant of midazolam hydroxylation variability in expressors.","evidence":"Genotype-stratified protein/mRNA quantification and microsomal activity assays in liver and jejunum","pmids":["12065767"],"confidence":"High","gaps":["Did not explain why *3 transcripts are absent at the protein level","Substrate range beyond midazolam not defined"]},{"year":2005,"claim":"Resolved the post-transcriptional mechanism by which CYP3A5*3 abolishes expression, showing aberrant exon 3B transcripts are eliminated by NMD.","evidence":"Minigene transfection, UPF1 siRNA, cycloheximide, and PTC mutagenesis in MCF7/HepG2 cells","pmids":["15955870"],"confidence":"High","gaps":["Did not quantify residual leaky expression","Inducibility in *3/*3 carriers shown negative but mechanism of non-response not dissected"]},{"year":2005,"claim":"Demonstrated CYP3A5 resistance to mechanism-based inhibition, distinguishing its inactivation behavior from CYP3A4.","evidence":"Recombinant enzyme assays, MIC spectrophotometry, and time-dependent inhibition kinetics with verapamil metabolites","pmids":["15689501"],"confidence":"High","gaps":["Structural basis of differential MIC formation not resolved at this stage","Limited to verapamil-class inhibitors"]},{"year":2006,"claim":"Characterized CYP3A5 as a high-efficiency tacrolimus-metabolizing enzyme in liver and kidney, explaining genotype-dependent immunosuppressant clearance.","evidence":"Recombinant enzyme kinetics and genotyped liver/kidney microsomes with LC-MS/MS metabolite quantification","pmids":["15951320","16501005"],"confidence":"High","gaps":["In vivo clinical dosing consequences not addressed mechanistically here","Structural determinant of efficiency unknown"]},{"year":2007,"claim":"Showed CYP3A5 is the dominant catalyst of vincristine metabolism in expressers, extending its substrate scope to anticancer drugs.","evidence":"cDNA-expressed enzyme kinetics, genotyped microsomes, and protein-correlation regression","pmids":["17272675"],"confidence":"High","gaps":["Clinical neurotoxicity link not established here","Single-lab dataset"]},{"year":2013,"claim":"Revealed sex-dependent transcriptional control of CYP3A5 via differential nuclear-receptor activation, explaining female-biased expression.","evidence":"Sex-stratified primary hepatocytes, nuclear translocation, EMSA, HNF-4α siRNA, and reporter assays","pmids":["22994453"],"confidence":"Medium","gaps":["Hormonal upstream signals not fully defined","Single lab; in vivo relevance not tested"]},{"year":2013,"claim":"Extended CYP3A5 metabolism to cyclosporine secondary metabolites and intrarenal disposition, with in vivo genotype-dependent PK consequences.","evidence":"Controlled human PK study with genotype stratification plus recombinant enzyme incubations","pmids":["23354298"],"confidence":"High","gaps":["Clinical nephrotoxicity link not mechanistically closed","Tissue-specific metabolite distribution not mapped"]},{"year":2016,"claim":"Defined a cell-autonomous oncologic role for CYP3A5 as a tumor drug-detoxification enzyme driving resistance, with HNF4A controlling basal and PXR controlling induced expression.","evidence":"Patient-derived pancreatic tumor models, shRNA knockdown, pharmacological inhibition, and transcription factor dissection","pmids":["26855150"],"confidence":"High","gaps":["Generality across tumor types not established","Direct PXR binding sites on the CYP3A5 locus not mapped here"]},{"year":2015,"claim":"Implicated CYP3A5 in androgen receptor signaling, showing it promotes AR nuclear translocation and prostate cancer cell growth.","evidence":"siRNA, azamulin inhibition, rifampicin induction, cell fractionation, and AR target gene readouts in prostate cancer lines","pmids":["25586052"],"confidence":"Medium","gaps":["Whether the effect requires catalytic activity vs a non-catalytic role is unresolved","Direct AR-CYP3A5 physical interaction not demonstrated"]},{"year":2019,"claim":"Provided the structural explanation for CYP3A5's distinct substrate handling via crystallographic comparison with CYP3A4.","evidence":"2.20 Å X-ray structure of substrate-free CYP3A5 and comparison with CYP3A5-ritonavir and CYP3A4 structures","pmids":["30926609"],"confidence":"High","gaps":["Substrate-bound complexes for clinically relevant drugs not solved","Dynamics linking structure to catalytic efficiency not directly measured"]},{"year":2022,"claim":"Identified distal cis-regulatory inputs (a shared enhancer and an antisense lncRNA) that fine-tune CYP3A5 expression beyond the proximal promoter.","evidence":"4C, CRISPR enhancer deletion, reporter assays, lncRNA knockdown/overexpression, and liver eQTL correlation","pmids":["36045613","34320606"],"confidence":"High","gaps":["Mechanism of lncRNA-mediated repression not resolved","Interaction of distal enhancer with the core promoter factors not integrated"]},{"year":null,"claim":"How tissue-specific extrahepatic expression (lung, blood, skin, kidney, fetal liver) and the catalytic versus non-catalytic roles of CYP3A5 in AR signaling integrate into a unified physiological function remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No single model links drug metabolism, AR translocation, and tumor resistance","Endogenous physiological substrate(s) not definitively established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[3,4,5,15,16,18]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[3,4]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[19,20]}],"pathway":[{"term_id":"R-HSA-9748784","term_label":"Drug ADME","supporting_discovery_ids":[3,4,5,8]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[11,25]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[10,12,21]}],"complexes":[],"partners":["POR","CYB5A","PXR","HNF4A","RXRA","AR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P20815","full_name":"Cytochrome P450 3A5","aliases":["CYPIIIA5","Cytochrome P450-PCN3"],"length_aa":502,"mass_kda":57.1,"function":"A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins (PubMed:10681376, PubMed:11093772, PubMed:12865317, PubMed:2732228). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:10681376, PubMed:11093772, PubMed:12865317, PubMed:2732228). Exhibits high catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes 6beta-hydroxylation of the steroid hormones testosterone, progesterone, and androstenedione (PubMed:2732228). Catalyzes the oxidative conversion of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Also involved in the oxidative metabolism of xenobiotics, including calcium channel blocking drug nifedipine and immunosuppressive drug cyclosporine (PubMed:2732228)","subcellular_location":"Endoplasmic reticulum membrane; Microsome membrane","url":"https://www.uniprot.org/uniprotkb/P20815/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CYP3A5","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CYP3A5","total_profiled":1310},"omim":[{"mim_id":"614546","title":"EFAVIRENZ, POOR METABOLISM OF","url":"https://www.omim.org/entry/614546"},{"mim_id":"606534","title":"CYTOCHROME P450, SUBFAMILY IIIA, POLYPEPTIDE 43; CYP3A43","url":"https://www.omim.org/entry/606534"},{"mim_id":"605340","title":"CYTOCHROME P450, SUBFAMILY IIIA, POLYPEPTIDE 7; CYP3A7","url":"https://www.omim.org/entry/605340"},{"mim_id":"605325","title":"CYTOCHROME P450, SUBFAMILY IIIA, POLYPEPTIDE 5; CYP3A5","url":"https://www.omim.org/entry/605325"},{"mim_id":"603254","title":"SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4; SMARCA4","url":"https://www.omim.org/entry/603254"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":167.3},{"tissue":"liver","ntpm":319.4}],"url":"https://www.proteinatlas.org/search/CYP3A5"},"hgnc":{"alias_symbol":["PCN3","P450PCN3","CP35"],"prev_symbol":[]},"alphafold":{"accession":"P20815","domains":[{"cath_id":"1.10.630.10","chopping":"86-495","consensus_level":"high","plddt":94.5384,"start":86,"end":495}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P20815","model_url":"https://alphafold.ebi.ac.uk/files/AF-P20815-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P20815-F1-predicted_aligned_error_v6.png","plddt_mean":93.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CYP3A5","jax_strain_url":"https://www.jax.org/strain/search?query=CYP3A5"},"sequence":{"accession":"P20815","fasta_url":"https://rest.uniprot.org/uniprotkb/P20815.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P20815/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P20815"}},"corpus_meta":[{"pmid":"25801146","id":"PMC_25801146","title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.","date":"2015","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25801146","citation_count":565,"is_preprint":false},{"pmid":"11740341","id":"PMC_11740341","title":"The genetic determinants of the CYP3A5 polymorphism.","date":"2001","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11740341","citation_count":563,"is_preprint":false},{"pmid":"12065767","id":"PMC_12065767","title":"Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.","date":"2002","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12065767","citation_count":366,"is_preprint":false},{"pmid":"16501005","id":"PMC_16501005","title":"Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro.","date":"2006","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/16501005","citation_count":251,"is_preprint":false},{"pmid":"15102541","id":"PMC_15102541","title":"Genetic variability in CYP3A5 and its possible consequences.","date":"2004","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/15102541","citation_count":214,"is_preprint":false},{"pmid":"15951320","id":"PMC_15951320","title":"Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.","date":"2005","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15951320","citation_count":188,"is_preprint":false},{"pmid":"26855150","id":"PMC_26855150","title":"CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.","date":"2016","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26855150","citation_count":173,"is_preprint":false},{"pmid":"15116055","id":"PMC_15116055","title":"CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.","date":"2004","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/15116055","citation_count":160,"is_preprint":false},{"pmid":"17049058","id":"PMC_17049058","title":"CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study.","date":"2006","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/17049058","citation_count":144,"is_preprint":false},{"pmid":"12817518","id":"PMC_12817518","title":"The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.","date":"2003","source":"Journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12817518","citation_count":136,"is_preprint":false},{"pmid":"9070608","id":"PMC_9070608","title":"Expression and localization of CYP3A4 and CYP3A5 in human lung.","date":"1997","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9070608","citation_count":133,"is_preprint":false},{"pmid":"15833928","id":"PMC_15833928","title":"CYP3A5 genetic polymorphisms in different ethnic populations.","date":"2005","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/15833928","citation_count":133,"is_preprint":false},{"pmid":"17272675","id":"PMC_17272675","title":"Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes.","date":"2007","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17272675","citation_count":112,"is_preprint":false},{"pmid":"15548719","id":"PMC_15548719","title":"CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15548719","citation_count":111,"is_preprint":false},{"pmid":"14504207","id":"PMC_14504207","title":"CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.","date":"2003","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/14504207","citation_count":94,"is_preprint":false},{"pmid":"20415563","id":"PMC_20415563","title":"CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.","date":"2010","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/20415563","citation_count":88,"is_preprint":false},{"pmid":"8877031","id":"PMC_8877031","title":"Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue.","date":"1996","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8877031","citation_count":84,"is_preprint":false},{"pmid":"15698606","id":"PMC_15698606","title":"CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.","date":"2005","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15698606","citation_count":82,"is_preprint":false},{"pmid":"30980418","id":"PMC_30980418","title":"CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review.","date":"2019","source":"Journal of clinical pharmacy and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30980418","citation_count":79,"is_preprint":false},{"pmid":"25930089","id":"PMC_25930089","title":"CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.","date":"2015","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/25930089","citation_count":76,"is_preprint":false},{"pmid":"15808586","id":"PMC_15808586","title":"Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.","date":"2005","source":"Transplantation proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/15808586","citation_count":74,"is_preprint":false},{"pmid":"29563827","id":"PMC_29563827","title":"CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.","date":"2018","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29563827","citation_count":72,"is_preprint":false},{"pmid":"22277678","id":"PMC_22277678","title":"Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system.","date":"2012","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/22277678","citation_count":70,"is_preprint":false},{"pmid":"18978522","id":"PMC_18978522","title":"CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.","date":"2008","source":"Therapeutic drug monitoring","url":"https://pubmed.ncbi.nlm.nih.gov/18978522","citation_count":69,"is_preprint":false},{"pmid":"39650550","id":"PMC_39650550","title":"CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms.","date":"2024","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/39650550","citation_count":68,"is_preprint":false},{"pmid":"29325225","id":"PMC_29325225","title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.","date":"2018","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/29325225","citation_count":68,"is_preprint":false},{"pmid":"28558634","id":"PMC_28558634","title":"Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.","date":"2017","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28558634","citation_count":66,"is_preprint":false},{"pmid":"15689501","id":"PMC_15689501","title":"Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.","date":"2005","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/15689501","citation_count":61,"is_preprint":false},{"pmid":"11745731","id":"PMC_11745731","title":"CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies.","date":"2001","source":"Journal of pharmaceutical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11745731","citation_count":57,"is_preprint":false},{"pmid":"21922127","id":"PMC_21922127","title":"Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.","date":"2011","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21922127","citation_count":55,"is_preprint":false},{"pmid":"15882469","id":"PMC_15882469","title":"CYP3A4 and CYP3A5 genotyping by Pyrosequencing.","date":"2005","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15882469","citation_count":55,"is_preprint":false},{"pmid":"19022943","id":"PMC_19022943","title":"Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.","date":"2008","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/19022943","citation_count":54,"is_preprint":false},{"pmid":"12814460","id":"PMC_12814460","title":"CYP3A5 phenotype-genotype correlations in a British population.","date":"2003","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12814460","citation_count":52,"is_preprint":false},{"pmid":"19910514","id":"PMC_19910514","title":"Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques.","date":"2009","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/19910514","citation_count":51,"is_preprint":false},{"pmid":"20030680","id":"PMC_20030680","title":"Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation.","date":"2010","source":"Clinical transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/20030680","citation_count":49,"is_preprint":false},{"pmid":"17372036","id":"PMC_17372036","title":"CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt.","date":"2007","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/17372036","citation_count":49,"is_preprint":false},{"pmid":"17339868","id":"PMC_17339868","title":"Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil.","date":"2007","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17339868","citation_count":45,"is_preprint":false},{"pmid":"29115708","id":"PMC_29115708","title":"CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.","date":"2017","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29115708","citation_count":43,"is_preprint":false},{"pmid":"19530969","id":"PMC_19530969","title":"Statin regulation of CYP3A4 and CYP3A5 expression.","date":"2009","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/19530969","citation_count":41,"is_preprint":false},{"pmid":"28849250","id":"PMC_28849250","title":"Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.","date":"2017","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28849250","citation_count":41,"is_preprint":false},{"pmid":"29775201","id":"PMC_29775201","title":"Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients.","date":"2018","source":"Journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29775201","citation_count":39,"is_preprint":false},{"pmid":"35202484","id":"PMC_35202484","title":"PharmVar GeneFocus: CYP3A5.","date":"2022","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35202484","citation_count":38,"is_preprint":false},{"pmid":"8946469","id":"PMC_8946469","title":"Selective expression of CYP3A5 and not CYP3A4 in human blood.","date":"1996","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8946469","citation_count":37,"is_preprint":false},{"pmid":"27450182","id":"PMC_27450182","title":"Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.","date":"2016","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/27450182","citation_count":36,"is_preprint":false},{"pmid":"15955870","id":"PMC_15955870","title":"CYP3A5 mRNA degradation by nonsense-mediated mRNA decay.","date":"2005","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15955870","citation_count":36,"is_preprint":false},{"pmid":"21544031","id":"PMC_21544031","title":"Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.","date":"2011","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/21544031","citation_count":35,"is_preprint":false},{"pmid":"30926609","id":"PMC_30926609","title":"Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30926609","citation_count":34,"is_preprint":false},{"pmid":"17116727","id":"PMC_17116727","title":"Characterization of androgen-regulated expression of CYP3A5 in human prostate.","date":"2006","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17116727","citation_count":32,"is_preprint":false},{"pmid":"33775687","id":"PMC_33775687","title":"Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance.","date":"2021","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/33775687","citation_count":30,"is_preprint":false},{"pmid":"22994453","id":"PMC_22994453","title":"Inherent sex-dependent regulation of human hepatic CYP3A5.","date":"2013","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22994453","citation_count":29,"is_preprint":false},{"pmid":"23354298","id":"PMC_23354298","title":"CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition.","date":"2013","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/23354298","citation_count":28,"is_preprint":false},{"pmid":"17667794","id":"PMC_17667794","title":"CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans.","date":"2007","source":"Therapeutic drug monitoring","url":"https://pubmed.ncbi.nlm.nih.gov/17667794","citation_count":27,"is_preprint":false},{"pmid":"19290795","id":"PMC_19290795","title":"CYP3A5 and ABCB1 genes and hypertension.","date":"2009","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/19290795","citation_count":26,"is_preprint":false},{"pmid":"29427770","id":"PMC_29427770","title":"Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.","date":"2018","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/29427770","citation_count":26,"is_preprint":false},{"pmid":"18211618","id":"PMC_18211618","title":"Frequencies of CYP3A5 genotypes and haplotypes in a Korean population.","date":"2008","source":"Journal of clinical pharmacy and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18211618","citation_count":26,"is_preprint":false},{"pmid":"17701008","id":"PMC_17701008","title":"Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers.","date":"2007","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17701008","citation_count":26,"is_preprint":false},{"pmid":"33805706","id":"PMC_33805706","title":"SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability.","date":"2021","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33805706","citation_count":25,"is_preprint":false},{"pmid":"20345875","id":"PMC_20345875","title":"CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility.","date":"2011","source":"International journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/20345875","citation_count":24,"is_preprint":false},{"pmid":"24351870","id":"PMC_24351870","title":"Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients.","date":"2013","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/24351870","citation_count":24,"is_preprint":false},{"pmid":"28408884","id":"PMC_28408884","title":"Effect of CYP3A4 and CYP3A5 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects.","date":"2017","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28408884","citation_count":24,"is_preprint":false},{"pmid":"24378577","id":"PMC_24378577","title":"Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.","date":"2014","source":"Therapeutic drug monitoring","url":"https://pubmed.ncbi.nlm.nih.gov/24378577","citation_count":23,"is_preprint":false},{"pmid":"25979262","id":"PMC_25979262","title":"Variability in Expression of CYP3A5 in Human Fetal Liver.","date":"2015","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/25979262","citation_count":22,"is_preprint":false},{"pmid":"23780963","id":"PMC_23780963","title":"The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine.","date":"2013","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/23780963","citation_count":22,"is_preprint":false},{"pmid":"21743379","id":"PMC_21743379","title":"CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.","date":"2011","source":"Therapeutic drug monitoring","url":"https://pubmed.ncbi.nlm.nih.gov/21743379","citation_count":22,"is_preprint":false},{"pmid":"31322243","id":"PMC_31322243","title":"miR‑543 acts as a novel oncogene in oral squamous cell carcinoma by targeting CYP3A5.","date":"2019","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/31322243","citation_count":22,"is_preprint":false},{"pmid":"26302866","id":"PMC_26302866","title":"CYP3A5 mediates bioactivation and cytotoxicity of tetrandrine.","date":"2015","source":"Archives of toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/26302866","citation_count":20,"is_preprint":false},{"pmid":"21039054","id":"PMC_21039054","title":"Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients.","date":"2010","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/21039054","citation_count":20,"is_preprint":false},{"pmid":"25778465","id":"PMC_25778465","title":"Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.","date":"2015","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/25778465","citation_count":20,"is_preprint":false},{"pmid":"19205682","id":"PMC_19205682","title":"Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort.","date":"2009","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19205682","citation_count":20,"is_preprint":false},{"pmid":"17605821","id":"PMC_17605821","title":"Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.","date":"2007","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17605821","citation_count":19,"is_preprint":false},{"pmid":"25586052","id":"PMC_25586052","title":"CYP3A5 regulates prostate cancer cell growth by facilitating nuclear translocation of AR.","date":"2015","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/25586052","citation_count":18,"is_preprint":false},{"pmid":"11485307","id":"PMC_11485307","title":"Cooperative regulation of CYP3A5 gene transcription by NF-Y and Sp family members.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11485307","citation_count":18,"is_preprint":false},{"pmid":"24438215","id":"PMC_24438215","title":"CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.","date":"2014","source":"Pediatric transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/24438215","citation_count":18,"is_preprint":false},{"pmid":"23501331","id":"PMC_23501331","title":"Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.","date":"2013","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23501331","citation_count":18,"is_preprint":false},{"pmid":"31922058","id":"PMC_31922058","title":"Melding Pharmacogenomic Effect of MDR1 and CYP3A5 Gene Polymorphism on Tacrolimus Dosing in Renal Transplant Recipients in Northern India.","date":"2019","source":"Kidney international reports","url":"https://pubmed.ncbi.nlm.nih.gov/31922058","citation_count":17,"is_preprint":false},{"pmid":"32657689","id":"PMC_32657689","title":"CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.","date":"2020","source":"South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde","url":"https://pubmed.ncbi.nlm.nih.gov/32657689","citation_count":17,"is_preprint":false},{"pmid":"33756436","id":"PMC_33756436","title":"Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis.","date":"2021","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/33756436","citation_count":16,"is_preprint":false},{"pmid":"26651976","id":"PMC_26651976","title":"Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugs.","date":"2016","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26651976","citation_count":15,"is_preprint":false},{"pmid":"36045613","id":"PMC_36045613","title":"Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5.","date":"2022","source":"Clinical and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/36045613","citation_count":15,"is_preprint":false},{"pmid":"25106522","id":"PMC_25106522","title":"Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population.","date":"2014","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/25106522","citation_count":15,"is_preprint":false},{"pmid":"28697165","id":"PMC_28697165","title":"Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.","date":"2017","source":"Journal of pediatric hematology/oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28697165","citation_count":15,"is_preprint":false},{"pmid":"33564260","id":"PMC_33564260","title":"Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension.","date":"2021","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33564260","citation_count":15,"is_preprint":false},{"pmid":"25894154","id":"PMC_25894154","title":"Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.","date":"2015","source":"Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/25894154","citation_count":15,"is_preprint":false},{"pmid":"21814220","id":"PMC_21814220","title":"Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension.","date":"2011","source":"Hypertension research : official journal of the Japanese Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/21814220","citation_count":15,"is_preprint":false},{"pmid":"24443221","id":"PMC_24443221","title":"Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.","date":"2014","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24443221","citation_count":15,"is_preprint":false},{"pmid":"26293521","id":"PMC_26293521","title":"Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.","date":"2015","source":"Clinical drug investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26293521","citation_count":14,"is_preprint":false},{"pmid":"32848803","id":"PMC_32848803","title":"CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32848803","citation_count":14,"is_preprint":false},{"pmid":"29135906","id":"PMC_29135906","title":"Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.","date":"2017","source":"Therapeutic drug monitoring","url":"https://pubmed.ncbi.nlm.nih.gov/29135906","citation_count":14,"is_preprint":false},{"pmid":"37645617","id":"PMC_37645617","title":"A systematic review and meta-analysis recite the efficacy of Tacrolimus treatment in renal transplant patients in association with genetic variants of CYP3A5 gene.","date":"2023","source":"American journal of clinical and experimental urology","url":"https://pubmed.ncbi.nlm.nih.gov/37645617","citation_count":13,"is_preprint":false},{"pmid":"27110018","id":"PMC_27110018","title":"CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.","date":"2016","source":"Transplantation proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/27110018","citation_count":13,"is_preprint":false},{"pmid":"36688864","id":"PMC_36688864","title":"Genetic association in CYP3A4 and CYP3A5 genes elevate the risk of prostate cancer.","date":"2023","source":"Annals of human biology","url":"https://pubmed.ncbi.nlm.nih.gov/36688864","citation_count":12,"is_preprint":false},{"pmid":"34320606","id":"PMC_34320606","title":"Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism.","date":"2022","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34320606","citation_count":12,"is_preprint":false},{"pmid":"34523354","id":"PMC_34523354","title":"Polymorphisms in the CYP3A5 gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation.","date":"2021","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/34523354","citation_count":12,"is_preprint":false},{"pmid":"31408697","id":"PMC_31408697","title":"The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism.","date":"2019","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31408697","citation_count":12,"is_preprint":false},{"pmid":"32971783","id":"PMC_32971783","title":"Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation.","date":"2020","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/32971783","citation_count":12,"is_preprint":false},{"pmid":"24368493","id":"PMC_24368493","title":"Interaction between ALOX5AP and CYP3A5 gene variants significantly increases the risk for cerebral infarctions in Chinese.","date":"2014","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/24368493","citation_count":12,"is_preprint":false},{"pmid":"26450467","id":"PMC_26450467","title":"Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.","date":"2015","source":"Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/26450467","citation_count":12,"is_preprint":false},{"pmid":"21380731","id":"PMC_21380731","title":"Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma.","date":"2011","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21380731","citation_count":12,"is_preprint":false},{"pmid":"29227563","id":"PMC_29227563","title":"Expression and enzyme activity of cytochrome P450 enzymes CYP3A4 and CYP3A5 in human skin and tissue-engineered skin equivalents.","date":"2018","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/29227563","citation_count":12,"is_preprint":false},{"pmid":"35338956","id":"PMC_35338956","title":"ABCG2, SCN1A and CYP3A5 genes polymorphism and drug-resistant epilepsy in children: A case-control study.","date":"2022","source":"Seizure","url":"https://pubmed.ncbi.nlm.nih.gov/35338956","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":60787,"output_tokens":7866,"usd":0.150175,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17152,"output_tokens":4026,"usd":0.093205,"stage2_stop_reason":"end_turn"},"total_usd":0.24338,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"A SNP within intron 3 (g.6986G>A, CYP3A5*3) is the primary genetic cause of the CYP3A5 protein polymorphism; the *3 allele leads to improper mRNA splicing and consequent loss of CYP3A5 protein expression, while the *1 allele permits normal splicing and protein expression.\",\n      \"method\": \"High-density SNP mapping of CYP3A5 variants in 183 Caucasian liver samples correlated with CYP3A5 protein expression; ethnic allele frequency analysis\",\n      \"journal\": \"Pharmacogenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated independently across multiple labs and ethnic groups, with direct genotype-phenotype correlation in large tissue panels\",\n      \"pmids\": [\"11740341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CYP3A5 protein contributes substantially (~31%) to the variability in hepatic midazolam 1'-hydroxylation activity; in livers carrying at least one CYP3A5*1 allele, CYP3A5 represented >50% of total CYP3A content, and improperly spliced mRNA (SV1-CYP3A5) was found only in tissues carrying a CYP3A5*3 allele.\",\n      \"method\": \"Quantitative protein and mRNA analysis of a panel of human liver and jejunal samples with genotype stratification; midazolam hydroxylation activity assays in liver microsomes\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (protein quantification, mRNA analysis, functional enzyme assay) in well-characterized tissue bank with genotype stratification\",\n      \"pmids\": [\"12065767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CYP3A5 mRNA splice variants containing exon 3B (arising from the CYP3A5*3 allele) are degraded by nonsense-mediated mRNA decay (NMD) due to premature termination codons in exon 3B; cycloheximide (ribosome inhibitor) and UPF1 siRNA both reduced decay of these splice variants, confirming NMD involvement. Barbiturate or steroid induction did not switch on CYP3A5 phenotypic expression in *3/*3 carriers.\",\n      \"method\": \"CYP3A5 minigene transfection in MCF7 cells; endogenous gene in HepG2 cells; cycloheximide treatment; UPF1 siRNA knockdown; PTC mutagenesis of exon 3B\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal mechanistic approaches (minigene, siRNA, mutagenesis, pharmacological inhibition) in one study, confirming NMD as the degradation mechanism\",\n      \"pmids\": [\"15955870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CYP3A5 metabolizes tacrolimus with a catalytic efficiency (Vmax/Km) approximately 64% higher than CYP3A4 for 13-O-demethyltacrolimus formation; CYP3A5 contributes 1.5–40% (median 18.8%) of total hepatic 13-O-demethylation of tacrolimus, and mean in vivo hepatic clearance is approximately 2.4-fold higher in CYP3A5 expressors versus non-expressors.\",\n      \"method\": \"In vitro kinetics with cDNA-expressed CYP3A4, CYP3A5, and CYP3A7; human liver microsomes stratified by CYP3A5 genotype; LC-MS/MS metabolite quantification; parallel-tube liver model scaling\",\n      \"journal\": \"Clinical chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro kinetic characterization with recombinant enzymes and genotyped microsomes, replicated by independent group (PMID 16501005)\",\n      \"pmids\": [\"15951320\", \"16501005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Recombinant CYP3A5 generates tacrolimus metabolites 13-O-desmethyl tacrolimus (major), 15-O-desmethyl tacrolimus, 31-O-desmethyl tacrolimus, and 12-hydroxy tacrolimus with an intrinsic clearance twice that of CYP3A4; formation of 13-DMT, 31-DMT, and 12-HT was ≥1.7-fold higher in CYP3A5*1/*3 microsomes than in *3/*3 microsomes. CYP3A5 also contributes substantially to renal tacrolimus metabolism (13-DMT formation 13.5-fold higher in *1/*3 kidney microsomes).\",\n      \"method\": \"In vitro enzyme kinetics with heterologously expressed CYP3A4 and CYP3A5; genotyped human liver and kidney microsomes; metabolite identification and quantification\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted enzyme kinetics with recombinant proteins plus genotyped human tissue microsomes, two independent datasets\",\n      \"pmids\": [\"16501005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CYP3A5 preferentially metabolizes vincristine to a secondary amine metabolite (M1) with 9- to 14-fold higher intrinsic clearance than CYP3A4 using cDNA-expressed enzymes; in CYP3A5 high-expressers, CYP3A5 accounts for 54–95% of total M1 formation activity, and the rate of M1 formation correlates tightly with CYP3A5 protein content (r²=0.95). Estimated hepatic clearance is ~5-fold higher in CYP3A5 high-expressers.\",\n      \"method\": \"cDNA-expressed enzyme kinetics; genotyped human liver microsome bank; Western blot protein quantification; selective chemical inhibition; linear regression analysis\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — recombinant enzyme kinetics combined with genotyped microsomal bank and selective chemical inhibition, single lab\",\n      \"pmids\": [\"17272675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Verapamil and its metabolite N-desalkylverapamil (D617) have little inhibitory effect on CYP3A5 and do not form a metabolic-intermediate complex (MIC) with CYP3A5, in contrast to their potent mechanism-based inhibition of CYP3A4. Norverapamil causes only modest time-dependent inhibition of CYP3A5 (30% at 50 µM) versus 80% for CYP3A4, with inactivation efficiency ~45-fold lower for CYP3A5. Human liver microsomes expressing CYP3A5 are correspondingly less inhibited by verapamil.\",\n      \"method\": \"cDNA-expressed CYP3A4 and CYP3A5 enzyme assays; dual-beam spectrophotometry for MIC detection; time-dependent inhibition kinetics (kinact, KI determination); genotyped human liver microsomes\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with recombinant enzymes, MIC spectrophotometry, kinetic parameter determination, and human microsome validation in a single focused study\",\n      \"pmids\": [\"15689501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CYP3A5 metabolizes quetiapine with an intrinsic clearance <35% of CYP3A4; CYP3A5 produces a different metabolite pattern (higher proportion of O-desalkylquetiapine relative to CYP3A4); cytochrome b5 co-expression increases CYP3A4 CL_int ~3-fold but has no effect on CYP3A5 CL_int, revealing a distinct interaction of CYP3A5 with cytochrome b5.\",\n      \"method\": \"Substrate depletion kinetics in insect cell microsomes expressing CYP3A4 or CYP3A5 ± cytochrome b5; metabolite profiling\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous in vitro kinetics with recombinant enzymes and orthogonal metabolite profiling, but single lab, single study\",\n      \"pmids\": [\"19022943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CYP3A5 contributes to the formation of secondary cyclosporine A metabolites AM19 and AM1c9 (from AM1 and AM1c precursors); CYP3A5 expressors have ~47–51% higher AUC for AM19 and AM1c9 versus non-expressors in vivo, and ~20% lower apparent urinary CsA clearance, indicating CYP3A5-dependent intrarenal CsA metabolism.\",\n      \"method\": \"Oral CsA administration to 24 healthy volunteers stratified by CYP3A5 genotype; whole blood/urine metabolite measurement by LC-MS; in vitro incubations of CsA metabolites with recombinant CYP3A4 and CYP3A5\",\n      \"journal\": \"Transplantation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — combined in vitro recombinant enzyme studies and controlled human pharmacokinetic study with genotype stratification\",\n      \"pmids\": [\"23354298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CYP3A5 mediates intrinsic and acquired drug resistance in pancreatic ductal adenocarcinoma by metabolically inactivating tyrosine kinase inhibitors and paclitaxel; CYP3A5 basal expression is controlled by HNF4A, while drug-induced upregulation is mediated by nuclear receptor NR1I2 (PXR); shRNA or pharmacological CYP3A5 inhibition re-sensitizes resistant tumor cells to these drugs.\",\n      \"method\": \"Patient-derived tumor cell models; shRNA knockdown; pharmacological inhibition; mechanistic dissection of HNF4A and NR1I2 regulation; drug sensitivity assays\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (shRNA, pharmacological inhibition, transcription factor dissection) in patient-derived models, published in high-impact peer-reviewed journal\",\n      \"pmids\": [\"26855150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Transcription of the CYP3A5 gene is cooperatively regulated by NF-Y (binding CCAAT box at -78/-68) and Sp1/Sp3 (binding the basic transcription element BTE at -67/-46) in HepG2 cells; mutation of either element alone decreases transcriptional activity to 10–21% of wild-type, while mutation of both reduces it to 4%.\",\n      \"method\": \"5'-truncated promoter-luciferase chimeric gene transfection in HepG2 cells; gel shift assays (EMSA) with nuclear extracts; site-directed mutagenesis of CCAAT box and BTE\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — promoter deletion analysis, EMSA, and mutagenesis in combination in a single focused study\",\n      \"pmids\": [\"11485307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CYP3A5 expression in human prostate is androgen-regulated: an androgen response element (ARE) in the CYP3A5 proximal promoter binds the androgen receptor (AR) as shown by EMSA, and androgen induction is abolished by mutation of this element. CYP3A5 mRNA is induced in LNCaP cells by androgen, suggesting CYP3A5 participates in an autoregulatory feedback loop controlling prostate cell androgen exposure by metabolizing testosterone.\",\n      \"method\": \"GeneChip analysis of prostate tissue after castration; RT-PCR of LNCaP cells; EMSA with ARE and AR; promoter mutation analysis; immunoblotting; immunohistochemistry; in situ hybridization\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — EMSA plus promoter mutagenesis establishing direct AR binding and androgen-dependent transcriptional control, supported by in vivo tissue data\",\n      \"pmids\": [\"17116727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CYP3A5 expression in human hepatocytes is sexually dimorphic (women > men), attributable to ~2-fold greater hormone-induced activation and nuclear accumulation of HNF-4α, PXR, and RXRα in female hepatocytes; PXR:RXRα shows higher DNA binding to its motif on the CYP3A5 promoter in female hepatocytes; HNF-4α siRNA knockdown and luciferase reporter assays confirmed this mechanism.\",\n      \"method\": \"Primary human hepatocyte cultures from male and female donors; nuclear translocation assays; EMSA/promoter binding assays; HNF-4α siRNA knockdown; CYP3A5 promoter-luciferase reporter in HepG2 cells\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal nuclear localization + promoter binding + siRNA + reporter assays, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"22994453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CYP3A5 regulates androgen receptor (AR) nuclear translocation in prostate cancer cells; CYP3A5 siRNA or the CYP3A5 inhibitor azamulin reduced growth of LNCaP, C4-2, and 22RV1 cells by 30–60%, decreased AR nuclear localization in response to DHT/R1881, and diminished PSA and TMPRSS2 expression. Conversely, the CYP3A5 inducer rifampicin enhanced AR nuclear localization.\",\n      \"method\": \"CYP3A5 siRNA knockdown; pharmacological inhibition (azamulin); CYP3A5 induction (rifampicin); cell fractionation; immunocytochemistry; growth assays; downstream AR target gene expression\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA plus pharmacological modulation with multiple cellular readouts (localization, growth, target genes), single lab\",\n      \"pmids\": [\"25586052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CYP3A5 mediates the bioactivation and cytotoxicity of the bisbenzylisoquinoline alkaloid tetrandrine by generating a reactive quinone methide intermediate; a WI-38 cell line transgenically expressing Cyp3a5 showed higher ROS, higher LDH release, lower GSH, and more apoptosis (elevated caspase-3, reduced Bcl-2) than vector-transfected controls after tetrandrine treatment.\",\n      \"method\": \"Cyp3a5-transgenic WI-38 cell line; ROS measurement; LDH assay; GSH assay; caspase-3 and Bcl-2 Western blot; apoptosis flow cytometry\",\n      \"journal\": \"Archives of toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isogenic cell model with multiple orthogonal cytotoxicity readouts, single lab\",\n      \"pmids\": [\"26302866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Both CYP3A4 and CYP3A5 bioactivate lapatinib via O-dealkylation to a reactive quinoneimine that forms glutathione adducts, but CYP3A4 is ~4–5-fold more efficient (kcat/Km) than CYP3A5 for both O-dealkylation and GSH adduct formation; CYP3A4-selective inhibitors reduced GSH adduct formation by 72–78% versus >90% for pan-CYP3A inhibition, indicating the remaining 16–22% is CYP3A5-mediated.\",\n      \"method\": \"cDNA-expressed recombinant P450 panel; Km/kcat kinetics; LC-MS/MS metabolite and GSH adduct quantification; CYP3A4-selective inhibitors (SR-9186, CYP3cide) in pooled human liver microsomes\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted enzyme kinetics with recombinant proteins, selective chemical inhibitors, and mass spectrometric metabolite quantification in one study\",\n      \"pmids\": [\"27450182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CYP3A4 and CYP3A5 both oxidize vinorelbine with equivalent Michaelis-Menten constants in recombinant systems (Km ~2.6 vs 3.6 µM; common Vmax ~1.4 pmol/min/pmol), but produce qualitatively different metabolite patterns; in human liver microsomes, intrinsic clearance correlates with CYP3A4 activity and does not significantly differ between CYP3A5 high and low expressers, indicating minimal contribution of polymorphic CYP3A5 to systemic vinorelbine clearance.\",\n      \"method\": \"cDNA-expressed CYP3A4+b5 and CYP3A5+b5 kinetics; radiolabeled vinorelbine; NMR and mass spectrometry metabolite characterization; genotyped human liver microsomes; CYP3A4 activity correlation\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous in vitro reconstitution with structural metabolite characterization plus human microsomal validation, single lab\",\n      \"pmids\": [\"23780963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The X-ray crystal structure of substrate-free CYP3A5 (2.20 Å) reveals a larger active site and an open substrate access channel compared with substrate-free CYP3A4, arising partly from a higher trajectory of the helix F-F' connector and fewer π-CH interactions between phenylalanine residues forming the active-site roof in CYP3A5; comparison with the CYP3A5-ritonavir complex confirmed conserved structural features and differential plasticity that favors alternative ritonavir conformations compared with CYP3A4.\",\n      \"method\": \"X-ray crystallography of substrate-free CYP3A5 (2.20 Å); structural comparison with CYP3A5-ritonavir complex and CYP3A4 structures\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — high-resolution crystal structure with comparative structural analysis and functional interpretation, single lab but rigorous method\",\n      \"pmids\": [\"30926609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The relative contribution of CYP3A5 to 21-hydroxyeplerenone formation (Vmax/KM = 3.3) exceeds that of CYP3A4 (Vmax/KM = 1.9), while the 6β-hydroxyeplerenone metabolite is formed preferentially by CYP3A4, establishing eplerenone as a substrate with differential positional selectivity between the two CYP3A isoforms.\",\n      \"method\": \"In vitro microsomal incubations with recombinant CYP3A4 and CYP3A5; metabolite identification and kinetic parameter determination\",\n      \"journal\": \"Toxicology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — well-executed in vitro enzyme kinetics with recombinant enzymes, but single lab, focused on one substrate\",\n      \"pmids\": [\"31408697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CYP3A5 is the predominant CYP3A form expressed in human lung (mRNA detected in all 8 samples by RT-PCR), localized by immunohistochemistry to ciliated and mucous bronchial cells, bronchial glands, bronchiolar epithelium, alveolar type I and II epithelium, vascular and capillary endothelium, and alveolar macrophages, whereas CYP3A4 is expressed in only ~20% of individuals and in fewer cell types.\",\n      \"method\": \"Immunohistochemistry with CYP3A4- and CYP3A5-specific antipeptide antibodies; RT-PCR with gene-specific primers in human lung tissue\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal methods (IHC and RT-PCR) for localization in human tissue, single study but comprehensive cell-type characterization\",\n      \"pmids\": [\"9070608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CYP3A5 is selectively expressed in human peripheral blood, specifically in neutrophils (PMNs) but not in other blood cells; CYP3A4 is not detected in peripheral blood by PCR or immunoblot. Despite CYP3A5 protein presence in white cell homogenates, midazolam metabolism could not be detected in granulocyte or whole WBC preparations.\",\n      \"method\": \"Immunostaining of peripheral blood smears; RT-PCR with CYP3A-specific primers on PMN and mononuclear cell cDNA; immunoblotting with anti-CYP3A and anti-CYP3A5 antibodies; midazolam metabolism assay in WBC preparations\",\n      \"journal\": \"Pharmacogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (immunostaining, PCR, immunoblot, functional assay), but functional metabolic activity was negative\",\n      \"pmids\": [\"8946469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A distal regulatory region (DRR) ~several kb from CYP3A4 physically contacts the CYP3A4 promoter (detected by 4C chromatin conformation capture), acts as a shared transcriptional enhancer for CYP3A4, CYP3A5, and CYP3A7 (CRISPR deletion decreases expression of all three genes); SNPs rs776744/rs776742 within the DRR increase enhancer-driven reporter expression and are associated with 1.39-fold increased CYP3A5 mRNA in human liver.\",\n      \"method\": \"4C chromatin conformation capture; enhancer reporter assays; CRISPR-mediated DRR deletion; liver cohort (n=246) genotype-expression correlation; clinical cohort validation\",\n      \"journal\": \"Clinical and translational science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal mechanistic methods (4C, CRISPR, reporter assay, mutagenesis) validated in human liver cohort\",\n      \"pmids\": [\"36045613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A lncRNA (AC069294.1) generated antisense to CYP3A4 negatively regulates both CYP3A4 and CYP3A5 expression; knockdown of AC069294.1 in Huh7 cells increased CYP3A4 mRNA ~3-fold, while overexpression decreased CYP3A4 mRNA by 89% and also reduced CYP3A5 expression; the CYP3A4*1G SNP (rs2242480) is associated with increased AC069294.1 expression and decreased CYP3A5 mRNA by 39%.\",\n      \"method\": \"siRNA knockdown and overexpression of AC069294.1 in Huh7 cells; mRNA quantification; liver eQTL analysis; linkage disequilibrium analysis\",\n      \"journal\": \"Pharmacogenetics and genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional knockdown and overexpression with mRNA readouts plus human liver cohort correlation, single lab\",\n      \"pmids\": [\"34320606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CYP3A5 expression in human fetal liver (7–32 weeks postconception) is highly variable (235-fold for normally spliced mRNA); alternative splicing due to the CYP3A5*3 allele occurs in fetal liver as in adults; formation of 1'-OH midazolam varies 79-fold and the 1'-OH/4-OH MDZ ratio depends on CYP3A5*3 genotype, confirming functional CYP3A5 activity in fetal liver.\",\n      \"method\": \"Genotyping of fetal liver bank; RT-PCR quantification of normal and SV1 CYP3A5 mRNA; midazolam 1'- and 4-hydroxylation activity assays in fetal liver microsomes\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — combined genotyping, mRNA quantification, and functional enzyme assay in large fetal liver bank, single lab\",\n      \"pmids\": [\"25979262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CYP3A5 protein expression in renal tubular cells (assessed by immunohistochemistry of renal allograft biopsies) is associated with calcineurin inhibitor nephrotoxicity (CNIT): CYP3A5 positivity at the brush border of proximal tubules was present in 47% of CNIT biopsies versus 14% of controls, while distal tubule staining was reduced in CNIT (10% vs 39%), suggesting altered localization/expression pattern is linked to nephrotoxicity.\",\n      \"method\": \"Immunohistochemistry of renal allograft biopsies (n=103); genotyping for CYP3A5 and ABCB1 SNPs; correlation of protein expression with histological CNIT diagnosis\",\n      \"journal\": \"Transplantation\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — retrospective IHC in biopsies with no functional mechanistic follow-up; localization finding without causal mechanistic experiment\",\n      \"pmids\": [\"21544031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CYP3A5 protein expression is detected in human skin (and tissue-engineered skin equivalents) by gene and protein expression methods; functional testosterone metabolism (confirmed by mass spectrometry of metabolites) was demonstrated in tissue-engineered skin equivalents, establishing that CYP3A5 is enzymatically active in skin.\",\n      \"method\": \"RT-PCR and protein expression in human skin and tissue-engineered skin equivalents (TESEs); enzyme activity assay with fluorescent substrate; mass spectrometric analysis of testosterone metabolites in TESE lysates\",\n      \"journal\": \"Experimental dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional enzyme activity confirmed by mass spectrometry in a relevant tissue model, single lab\",\n      \"pmids\": [\"29227563\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CYP3A5 is a cytochrome P450 enzyme whose expression is primarily controlled by a common intronic splice-site variant (CYP3A5*3/g.6986G>A) that causes improper mRNA splicing and NMD-mediated degradation of aberrant transcripts; in expressors, transcription is cooperatively driven by NF-Y, Sp1/Sp3, PXR:RXRα, and HNF-4α acting on promoter elements, with an upstream distal enhancer and a cis-acting lncRNA providing additional regulatory inputs. When expressed, CYP3A5 hydroxylates and demethylates numerous drugs (notably tacrolimus, cyclosporine metabolites, vincristine, lapatinib, eplerenone, and tetrandrine) with catalytic efficiencies and positional selectivities that differ from CYP3A4, and unlike CYP3A4 is relatively resistant to mechanism-based inhibition by verapamil; in prostate cells CYP3A5 facilitates androgen receptor nuclear translocation (and is itself androgen-regulated via a promoter ARE), and in certain tumors it acts as a cell-autonomous drug-detoxification enzyme whose induction through NR1I2/PXR confers acquired drug resistance.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CYP3A5 is a cytochrome P450 monooxygenase that hydroxylates and demethylates a broad range of drugs and steroids, with catalytic efficiencies and positional selectivities that distinguish it from the closely related CYP3A4 [#3, #18]. Its expression in the population is governed primarily by the intronic CYP3A5*3 splice-site variant (g.6986G>A), which introduces aberrant exon 3B into the transcript; the resulting premature termination codons trigger UPF1-dependent nonsense-mediated decay, abolishing functional protein in *3/*3 individuals while *1 carriers retain expression [#0, #2]. In expressors, CYP3A5 can constitute more than half of total hepatic CYP3A and accounts for a substantial fraction of CYP3A-mediated drug metabolism [#1]. Functionally, CYP3A5 metabolizes tacrolimus, cyclosporine-derived metabolites, and vincristine with markedly higher intrinsic clearance than CYP3A4 [#3, #5, #8], produces distinct metabolite patterns for substrates such as quetiapine, vinorelbine, and eplerenone [#7, #16, #18], and is relatively resistant to the mechanism-based inhibition that verapamil exerts on CYP3A4 [#6]. Its enlarged, open active site and distinct helix F-F' geometry provide a structural basis for these isoform-specific catalytic behaviors [#17]. Beyond constitutive hepatic and extrahepatic expression, CYP3A5 transcription is cooperatively driven by NF-Y and Sp1/Sp3 at the proximal promoter [#10], by HNF-4\\u03b1 and PXR:RXR\\u03b1 in a sex-dependent manner [#12], and by a shared distal enhancer and an antisense lncRNA (AC069294.1) [#21, #22]. CYP3A5 also participates in cell-autonomous roles: it bioactivates compounds such as tetrandrine and lapatinib to reactive intermediates [#14, #15], confers PXR-driven drug resistance in pancreatic tumors by inactivating chemotherapeutics [#9], and in prostate cells facilitates androgen receptor nuclear translocation while being itself androgen-inducible through a promoter ARE [#11, #13].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established the genetic basis of the CYP3A5 expression polymorphism, answering why only a subset of individuals express functional protein.\",\n      \"evidence\": \"High-density SNP mapping correlated with protein expression in 183 liver samples\",\n      \"pmids\": [\"11740341\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the molecular fate of the aberrant transcript\", \"Did not address regulation in expressors\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified the core transcription factors driving CYP3A5 basal promoter activity, defining how the gene is expressed when permitted.\",\n      \"evidence\": \"Promoter-luciferase truncations, EMSA, and site-directed mutagenesis in HepG2 cells\",\n      \"pmids\": [\"11485307\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address inducible or nuclear-receptor-mediated regulation\", \"No distal regulatory elements examined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Quantified the contribution of CYP3A5 to hepatic CYP3A activity, showing it is a major determinant of midazolam hydroxylation variability in expressors.\",\n      \"evidence\": \"Genotype-stratified protein/mRNA quantification and microsomal activity assays in liver and jejunum\",\n      \"pmids\": [\"12065767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not explain why *3 transcripts are absent at the protein level\", \"Substrate range beyond midazolam not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Resolved the post-transcriptional mechanism by which CYP3A5*3 abolishes expression, showing aberrant exon 3B transcripts are eliminated by NMD.\",\n      \"evidence\": \"Minigene transfection, UPF1 siRNA, cycloheximide, and PTC mutagenesis in MCF7/HepG2 cells\",\n      \"pmids\": [\"15955870\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not quantify residual leaky expression\", \"Inducibility in *3/*3 carriers shown negative but mechanism of non-response not dissected\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated CYP3A5 resistance to mechanism-based inhibition, distinguishing its inactivation behavior from CYP3A4.\",\n      \"evidence\": \"Recombinant enzyme assays, MIC spectrophotometry, and time-dependent inhibition kinetics with verapamil metabolites\",\n      \"pmids\": [\"15689501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of differential MIC formation not resolved at this stage\", \"Limited to verapamil-class inhibitors\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Characterized CYP3A5 as a high-efficiency tacrolimus-metabolizing enzyme in liver and kidney, explaining genotype-dependent immunosuppressant clearance.\",\n      \"evidence\": \"Recombinant enzyme kinetics and genotyped liver/kidney microsomes with LC-MS/MS metabolite quantification\",\n      \"pmids\": [\"15951320\", \"16501005\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo clinical dosing consequences not addressed mechanistically here\", \"Structural determinant of efficiency unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed CYP3A5 is the dominant catalyst of vincristine metabolism in expressers, extending its substrate scope to anticancer drugs.\",\n      \"evidence\": \"cDNA-expressed enzyme kinetics, genotyped microsomes, and protein-correlation regression\",\n      \"pmids\": [\"17272675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical neurotoxicity link not established here\", \"Single-lab dataset\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed sex-dependent transcriptional control of CYP3A5 via differential nuclear-receptor activation, explaining female-biased expression.\",\n      \"evidence\": \"Sex-stratified primary hepatocytes, nuclear translocation, EMSA, HNF-4\\u03b1 siRNA, and reporter assays\",\n      \"pmids\": [\"22994453\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Hormonal upstream signals not fully defined\", \"Single lab; in vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended CYP3A5 metabolism to cyclosporine secondary metabolites and intrarenal disposition, with in vivo genotype-dependent PK consequences.\",\n      \"evidence\": \"Controlled human PK study with genotype stratification plus recombinant enzyme incubations\",\n      \"pmids\": [\"23354298\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical nephrotoxicity link not mechanistically closed\", \"Tissue-specific metabolite distribution not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined a cell-autonomous oncologic role for CYP3A5 as a tumor drug-detoxification enzyme driving resistance, with HNF4A controlling basal and PXR controlling induced expression.\",\n      \"evidence\": \"Patient-derived pancreatic tumor models, shRNA knockdown, pharmacological inhibition, and transcription factor dissection\",\n      \"pmids\": [\"26855150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality across tumor types not established\", \"Direct PXR binding sites on the CYP3A5 locus not mapped here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Implicated CYP3A5 in androgen receptor signaling, showing it promotes AR nuclear translocation and prostate cancer cell growth.\",\n      \"evidence\": \"siRNA, azamulin inhibition, rifampicin induction, cell fractionation, and AR target gene readouts in prostate cancer lines\",\n      \"pmids\": [\"25586052\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the effect requires catalytic activity vs a non-catalytic role is unresolved\", \"Direct AR-CYP3A5 physical interaction not demonstrated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided the structural explanation for CYP3A5's distinct substrate handling via crystallographic comparison with CYP3A4.\",\n      \"evidence\": \"2.20 \\u00c5 X-ray structure of substrate-free CYP3A5 and comparison with CYP3A5-ritonavir and CYP3A4 structures\",\n      \"pmids\": [\"30926609\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate-bound complexes for clinically relevant drugs not solved\", \"Dynamics linking structure to catalytic efficiency not directly measured\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified distal cis-regulatory inputs (a shared enhancer and an antisense lncRNA) that fine-tune CYP3A5 expression beyond the proximal promoter.\",\n      \"evidence\": \"4C, CRISPR enhancer deletion, reporter assays, lncRNA knockdown/overexpression, and liver eQTL correlation\",\n      \"pmids\": [\"36045613\", \"34320606\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of lncRNA-mediated repression not resolved\", \"Interaction of distal enhancer with the core promoter factors not integrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How tissue-specific extrahepatic expression (lung, blood, skin, kidney, fetal liver) and the catalytic versus non-catalytic roles of CYP3A5 in AR signaling integrate into a unified physiological function remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No single model links drug metabolism, AR translocation, and tumor resistance\", \"Endogenous physiological substrate(s) not definitively established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [3, 4, 5, 15, 16, 18]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3, 4]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": []}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [19, 20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [3, 4, 5, 8]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [11, 25]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [10, 12, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"POR\", \"CYB5A\", \"PXR\", \"HNF4A\", \"RXRA\", \"AR\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}